Turku PET Centre, University of Turku, Kiinamyllynkatu 4-8, Turku FI-20520, Finland.
Department of Chemistry, University of Turku, Henrikinkatu 2, Turku FI-20500, Finland.
Mol Pharm. 2024 Aug 5;21(8):4147-4156. doi: 10.1021/acs.molpharmaceut.4c00546. Epub 2024 Jul 15.
Fatty acid binding protein 3 (FABP3) is expressed both in tumor cells and in the tumor vasculature, making it a potential target for medical imaging and therapy. In this study, we aimed to radiolabel a CooP peptide with a free amino and thiol group, and evaluate the radiolabeled product [F]FNA--CooP for imaging FABP3 expression in breast cancer brain metastases by positron emission tomography. [F]FNA--CooP was prepared by highly chemoselective -acylation and characterized using different chemical approaches. We validated its binding to the target using in vitro tissue section autoradiography and performed stability tests in vitro and in vivo. [F]FNA--CooP was successfully synthesized in 16.8% decay-corrected radiochemical yield with high radiochemical purity (98.5%). It exhibited heterogeneous binding on brain metastasis tissue sections from a patient with breast cancer, with foci of radioactivity binding corresponding to FABP3 positivity. Furthermore, the tracer binding was reduced by 55% in the presence of nonradioactive FNA--CooP a blocker, indicating specific tracer binding and that FABP3 is a viable target for [F]FNA--CooP. Favorably, the tracer did not bind to necrotic tumor tissue. However, [F]FNA--CooP displayed limited stability both in vitro in mouse plasma or human serum and in vivo in mouse, therefore further studies are needed to improve the stability [F]FNA--CooP to be used for in vivo applications.
脂肪酸结合蛋白 3(FABP3)在肿瘤细胞和肿瘤血管中均有表达,使其成为医学成像和治疗的潜在靶点。在这项研究中,我们旨在用一个游离的氨基和巯基标记 CooP 肽,并评估放射性标记产物[F]FNA--CooP 通过正电子发射断层扫描用于乳腺癌脑转移中 FABP3 表达的成像。[F]FNA--CooP 通过高度化学选择性的酰化反应制备,并通过不同的化学方法进行了表征。我们使用体外组织切片放射自显影验证了其与靶标的结合,并进行了体外和体内稳定性测试。[F]FNA--CooP 以 16.8%的衰减校正放射性化学产率成功合成,具有高放射性化学纯度(98.5%)。它在来自乳腺癌患者的脑转移组织切片上表现出不均匀的结合,放射性结合的焦点与 FABP3 阳性相对应。此外,在存在非放射性 FNA--CooP(一种阻滞剂)的情况下,示踪剂的结合减少了 55%,表明特异性示踪剂结合,并且 FABP3 是[F]FNA--CooP 的可行靶点。有利的是,示踪剂未与坏死肿瘤组织结合。然而,[F]FNA--CooP 在体外(在小鼠血浆或人血清中)和体内(在小鼠中)均显示出有限的稳定性,因此需要进一步研究来提高[F]FNA--CooP 的稳定性,以用于体内应用。